FDA Peptide Reclassification 2026: What's Changing for BPC-157, TB-500 and More

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that the FDA intends to move roughly 14 therapeutic peptides from Category 2 back to Category 1 of the 503A compounding list. For patients and clinicians who have spent the past two and a half years watching BPC-157, TB-500, and similar peptides disappear from legitimate compounding channels, this is the first real signal that the door might reopen. But the announcement is regulatory intent, not yet law, and that distinction matters.

What Category 2 actually did

In September 2023, the FDA published a revised 503A bulk substance list that placed a group of therapeutic peptides into Category 2. Under FDA rules, Category 2 substances cannot be used by 503A compounding pharmacies to prepare patient-specific prescriptions. The agency cited immunogenicity concerns as the rationale. Peptides, because they are sequences of amino acids rather than small molecules, can in some cases trigger antibody responses that complicate safety, especially when the source material is not pharmaceutical grade or the preparation is not well characterized.

The practical effect of the 2023 designation was immediate. US compounding pharmacies that had been preparing BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu in injectable form, and epithalon for patient prescriptions stopped doing so almost overnight. Clinicians lost a legal supply channel, patients shifted toward research peptide sellers operating in a gray area, and a meaningful slice of functional medicine practice had to rebuild around what was still available.

What restoring Category 1 would unlock

If the FDA follows through on the February 27 announcement and publishes an updated category list, 503A pharmacies would again be able to prepare the restored peptides for patient-specific prescriptions written by licensed clinicians. That means a clinician could prescribe a protocol, send the script to a compounding pharmacy, and the pharmacy could fill it with a well-characterized, US-prepared preparation rather than the patient buying raw material online from an overseas seller.

The peptides expected to benefit, based on the published advocacy efforts and the patient populations most affected, include BPC-157, TB-500, injectable GHK-Cu, CJC-1295, ipamorelin, and epithalon. A handful of others in the same category are also candidates. Not every peptide on the 2023 Category 2 list is expected to move. GHRP-6 and DSIP, for example, are likely to stay in Category 2. They have thinner safety profiles, less research community advocacy, and the patient populations benefiting from them are small enough that the agency is unlikely to prioritize them.

The critical caveat

As of this writing, nothing has actually changed. The February 27 announcement was a statement of regulatory intent, delivered at a press event. It is not a federal register notice, it is not an updated 503A category list, and it is not a guidance document. Compounding pharmacies that start preparing BPC-157 or TB-500 today are still operating in violation of the 2023 designation, and the FDA could still enforce against them.

There is no published timeline for the formal rule change. These things typically move through HHS and the FDA at the pace of months rather than weeks, with opportunities for public comment and interagency review. The right posture right now is to treat the announcement as promising but pending, and to keep watching for a published rule or guidance document that names specific peptides and lists an effective date.

Separate tracks: WADA and research peptides

Two adjacent things are worth clarifying. First, the World Anti-Doping Agency has its own prohibited list, and WADA rules are completely separate from FDA compounding categories. BPC-157 is on the WADA S0 list (non-approved substances) and will stay there regardless of what the FDA does. Competitive athletes under WADA jurisdiction cannot use BPC-157 no matter how the 503A list evolves.

Second, the research peptide market, where products are sold online under a not-for-human-use label, is not a part of the 503A framework and never has been. A Category 1 restoration would not legalize, legitimize, or improve the quality of research peptides sold over the internet. Those products remain outside the FDA compounding system and should not be confused with pharmacy-prepared preparations.

What patients and clinicians should do now

Wait. The most valuable thing anyone can do in the next few months is monitor for the actual rule change rather than acting on the announcement. When a formal FDA document lands, it will name specific peptides, specify an effective date, and give 503A pharmacies the legal cover to resume preparation. Until then, patients seeking legitimate compounded peptides for prescribed protocols should talk with their clinician about what legal options exist in the current regulatory state.

For background on individual peptides that could be affected, our profile pages have the current clinical and regulatory details: BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, and epithalon. We will update each of those pages and this article when a formal rule change is published.